Results of a Phase 1, Single Ascending Dose, Placebo-Controlled Study of ABBV-8E12 in Patients with Progressive Supranuclear Palsy and Phase 2 Study Design
Objective: To present the results of a phase 1 study of ABBV-8E12 in subjects with Progressive Supranuclear Palsy (PSP) and design of a phase 2…Primary progressive apraxia: an unusual ideomotor syndrome
Objective: We describe and demonstrate by video 2 cases of primary ideomotor progressive apraxia with progressive difficulty with hand dexterity and manipulation and mild parkinsonism…Phenotypic Heterogeneity in PSP Variants – A Case Series
Objective: To present the phenotypic heterogeneity we observed in 5 PSP variants. Background: Progressive supranuclear palsy (PSP) is a primary tauopathy characterised by progressive gait…[18F]AV-1451 PET imaging of tau in progressive supranuclear palsy and Alzheimer’s disease
Objective: To evaluate: (1) brain tau pathology in vivo in patients with Progressive Supranuclear Palsy (PSP) and Alzheimer's disease (AD); (2) whether brain tau pathology…PET imaging of tau pathology in progressive supranuclear palsy
Objective: This study aimed to determine whether there is an increase in [18F]-AV-1451 uptake in the brains of progressive supranuclear palsy (PSP) patients compared to…Evaluation of the surface based measures to discriminate progressive supranuclear palsy from corticobasal syndrome
Objective: To evaluate structural gray matter (GM) changes tested by surface-based measures of cortical thickness (CTh), surface area (SA) and volume (VOL), in order to…In vivo evaluation of tau pathologies in patient with progressive supranuclear palsy and healthy subjects with [11C]PBB3-PET
Objective: This study was aimed at evaluating pathological tau accumulations in the brains of patients with progressive supranuclear palsy (PSP) and young and old healthy…Tau dysfunction in the basal ganglia of a mouse model of tauopathy related to PSP
Objective: Determine motor coordination and neurochemical phenotypes in the basal ganglia of mice lacking the Tau protein or expressing an abnormal content of Tau isoforms.…“Words untold”
Objective: To highlight the salient clinical and pathologic features of primary progressive apraxia of speech through a clinical case presentation. Background: Apraxia of speech is…Dorsal simultanagnosia as a cortical sign in the tauopathy spectrum
Objective: Clinical characterization of a tauopathy spectrum patient. Background: In recent years phenotypic overlap has been demonstrated between patients with progressive supranuclear palsy (PSP) pathology…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.